Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
A 5-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment—radiation, surgery, or active surveillance—in patients of all ages and ethnicities is creating a road map for the future regarding long-term bowel, bladder, and sexual function in order to clarify expectations and enable men to make informed choices about care.
The important ADMIRAL trial, reported by Perl et al in The New England Journal of Medicine1 and reviewed in this issue of The ASCO Post, shows the efficacy of a specific FLT3 inhibitor in patients with advanced acute myeloid leukemia (AML) and enhances the era of personalized medicine in leukemia.
The PD-L1 immune checkpoint inhibitor failed to show a superior improvement in overall survival (OS) in comparison with standard chemotherapy both in the overall population (median OS: 10.4 vs. 10.9 months; hazard ratio [HR] 0.91, 95% CI [0.74, 1.11]; p = 0.1779) and the PD-L1–positive population (median OS: 16.2 vs. 17.7 months;
Monika Joshi, MD, MRCP, associate professor of medicine, Division of Hematology-Oncology, and co-leader for Genitourinary Disease Team, at Penn State Hershey Cancer Institute, discusses the phase Ib/II results of a trial looking at concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of the bladder.
Combining cabozantinib (Cabmetyx) and atezolizumab (Tecentriq) induced durable responses in men with metastatic castration-resistant prostate cancer (CRPC) who had soft tissue progression after prior hormonal therapy.
The combination of regorafenib (Stivarga) plus an oral fluoropyrimidine, TAS-102, (trifluridine/tipiracil; Lonsurf), as third-line treatment in patients with metastatic colorectal cancer (mCRC) achieved a clinically meaningful disease control rate (DCR) .